<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00318760</url>
  </required_header>
  <id_info>
    <org_study_id>999905403</org_study_id>
    <secondary_id>05-DA-N403</secondary_id>
    <nct_id>NCT00318760</nct_id>
  </id_info>
  <brief_title>Effect of Clonidine on Responses to Imagery Scripts</brief_title>
  <official_title>Effect of Clonidine on Responses to Imagery Scripts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Research has shown that clonidine, a drug originally prescribed to treat high blood
      pressure and some symptoms of opioid withdrawal, can help block stress-induced relapse to
      heroin and cocaine seeking in rats. However, it does not seem to block cue-induced relapse in
      rats. Researchers are interested in studying whether clonidine shows the same pattern of
      effects on stress- and cue-induced cravings for heroin or cocaine in humans.

      Objectives:

      - To compare the ability of clonidine to reduce stress- and cue-induced cocaine and heroin
      craving in drug abusers.

      Eligibility:

      - Individuals between 18 and 55 years of age who are current cocaine or heroin users.

      Design:

        -  This study will consist of two visits: a screening visit to determine eligibility and an
           experimental/script session.

        -  Before the script session, participants will provide urine and breath samples for
           testing. Participants will complete questionnaires to measure their current drug craving
           and days since last use of cocaine or heroin.

        -  At the start of the script session, participants will receive a dose of clonidine or
           placebo as directed by the study researchers. Three hours after dosing, participants
           will be read four scripts (two neutral, one stress-inducing, and one drug-cue-related)
           with breaks in between each script. After each script, participants will respond to
           questions about levels of stress and craving.

        -  Participants will provide saliva samples immediately before and during the script
           readings, and will also be measured for skin response to the scripts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Stress and exposure to drug-related cues (environmental stimuli previously
      associated with drug availability) are considered factors that increase the risk of relapse
      to heroin and/or cocaine use. The two factors may act through different neural mechanisms.
      Alpha-2 adrenergic agonists, such as clonidine, have been shown to block stress-induced
      relapse, but not cue-induced relapse, to heroin and cocaine self-administration in rodents.
      The ability of clonidine to attenuate stress- or cue-induced heroin and cocaine craving in
      drug abusers has not been tested. It is important to determine, in humans, whether clonidine
      blocks the acute effects of only one putative class of relapse precipitants, or whether its
      effects are more general.

      Scientific goal. To compare the ability of clonidine to reduce stress-induced and cue-induced
      cocaine and heroin craving in drug abusers.

      Participant population. A total of up to 160 drug abusers using cocaine, heroin, or both will
      be enrolled. Target enrollment will include 40% women and 60% minorities (mostly
      African-American).

      Experimental design and methods. Participants will be randomized to one of three groups
      receiving clonidine 0.1 mg, clonidine 0.2 mg, or placebo orally under double-blind
      conditions. The study will consist of a single 5-6 hr experimental session in which there
      will be baseline measures, drug administration, and four script-guided imagery sets, each
      followed by a period of data collection. Three hours after dosing (when peak plasma clonidine
      concentrations are reached), participants will be exposed to four scripts: one
      stress-inducing, one describing drug cues, and two with neutral content. The standardized
      script-guided imagery procedure has previously been shown to reliably induce negative
      affective states (stress scripts) and/or craving (stress and drug-cue scripts) compared to
      the neutral scripts and to have internal and external validity (Tiffany and Drobes, 1990;
      Maude-Griffin and Tiffany, 1996; Taylor et al., 2000; Sinha et al., 1999, 2000, 2003;
      Singleton et al., 2003; Tiffany and Haekeneworth, 1991; Elash et al., 1995; Drobes and
      Tiffany, 1997; Taylor et al., 2000; Singleton et al., 2003). Outcome measures will include
      subjective ratings of drug craving and mood, autonomic response (galvanic skin response
      [GSR]), and endocrine responses (salivary cortisol and salivary ?-amylase, a measure of
      endogenous adrenergic activity during stress (Chatterton et al., 1996; Nater et al., 2005;
      van Stegeren et al., 2005)).

      Benefits to participants and/or society. There are no direct benefits to participants.
      However, if clonidine is effective in blocking stress-induced and/or cue-induced craving,
      then the results will be used as a basis for designing a treatment trial, and drug abusers
      and society may benefit from the eventual use of clonidine or other alpha agonists for
      prevention of relapse in cocaine and heroin users. In addition, this research will provide
      information on the clinical relevance of a preclinical model of relapse, possibly
      strengthening arguments for its use in medication development.

      Risks to participants. Participants may experience side effects from clonidine such as
      sedation and are expected to experience brief, mild psychological stress and drug craving
      from the laboratory script procedures. Prior to leaving the session, participants will be
      assessed for the presence of continued drug effects. If participants are experiencing any
      stress or craving at the end of the session, they will undergo a 10-minute guided relaxation
      session, which will be repeated until feelings of stress or craving dissipate, before being
      released from the laboratory. Participants may be kept longer than the planned session
      length, up to and including staying overnight on the inpatient ward, because of continued
      side effects or elevated stress or craving. If the MRP deems it medically necessary,
      participants will be sent to JHBMC emergency department for further evaluation and treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 14, 2005</start_date>
  <completion_date type="Actual">August 7, 2013</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective ratings of drug craving and mood</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Autonomic response (galvanic skin response [GSR])</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate and blood pressure</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endocrine responses (salivary cortisol and salivary alpha-amylase)</measure>
    <time_frame>1 hr</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Cocaine Abuse</condition>
  <condition>Heroin Abuse</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>0.1 or 0.2 mg oral, one dose</description>
    <arm_group_label>ARM 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsule 1 dose</description>
    <arm_group_label>ARM 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Age between 18 and 55;

               2. Evidence of current cocaine and/or heroin use (by self-report) with a minimum
                  lifetime drug-use duration of 1 year and a minimum current drug use of once in
                  the last 30 days;

                  EXCLUSION CRITERIA:

               1. Hypersensitivity to clonidine or any component of the formulation

               2. Schizophrenia or any other DSM-IV psychotic disorder; history of anxiety
                  disorder, panic disorder, bipolar disorder; current Major Depressive Disorder

               3. Current physical dependence on opioids, cocaine, alcohol, benzodiazepines or
                  other sedative-hypnotic; this is an exclusion criterion because we want to
                  evaluate the ability of clonidine to affect stress- and cue-induced drug craving
                  independent of its effects on drug withdrawal

               4. Cognitive impairment severe enough to preclude informed consent or valid
                  responses on questionnaires

               5. Pregnancy or breast feeding

               6. Severely impaired hepatic function

               7. Severely impaired renal function, with CLcr &lt; 10 ml/minute

               8. Medical conditions that contraindicate or that could complicate clonidine
                  administration:

                    1. hypotension (SBP &lt;95 or DBP &lt; 40 mm Hg) over several readings

                    2. hypertension(SBP &gt;160 mm Hg, DBP &gt;95 mm Hg) over several readings

                    3. orthostatic hypotension over several readings or as a consequence of any
                       underlying medical disorder (e.g., autonomic insufficiency)

                    4. bradycardia (heart rate &lt; 50 bpm) over several readings

                    5. cerebrovascular disease or any history of CVA or transient ischemic attack
                       (TIA)

                    6. documented coronary disease

                    7. serious arrhythmia or conduction defect (e.g., second or third degree heart
                       block, atrial fibrillation)

                    8. sinus node dysfunction, severe bradycardia or symptomatic bradycardia

                    9. congestive heart failure

               9. Medications that could interact adversely with clonidine: antipsychotics;
                  antihypertensives (e.g., beta blockers); antiepileptics; CNS depressants (e.g.
                  barbiturates, benzodiazepines, narcotic analgesics, alcohol, or other sedatives);
                  cyclosporine; oral hypoglycemic agents or insulin; levodopa; tricyclic
                  antidepressants; herbals such as dong quai, ephedra, yohimbe, ginseng, valerian,
                  St. John s wort, kava kava, gotu kola

              10. Women who are able to get pregnant and are not abstinent from sexual activity
                  must agree to use a medically effective form of contraception while in the study.
                  Those include:

               1. Hormonal contraceptives (birth control pills, injectable hormones, vaginal ring
                  hormones),

               2. Surgical sterility (tubal ligation or hysterectomy)

               3. IUD

               4. Diaphragm with spermicide

               5. Condom with spermicide

        Women who do not agree to use these medically effective forms of contraception while in the
        study will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenzie Preston, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute on Drug Abuse</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abduljawad KA, Langley RW, Bradshaw CM, Szabadi E. Effects of clonidine and diazepam on the acoustic startle response and on its inhibition by 'prepulses' in man. J Psychopharmacol. 1997;11(1):29-34.</citation>
    <PMID>9097890</PMID>
  </reference>
  <reference>
    <citation>Benschop RJ, Jacobs R, Sommer B, Sch√ºrmeyer TH, Raab JR, Schmidt RE, Schedlowski M. Modulation of the immunologic response to acute stress in humans by beta-blockade or benzodiazepines. FASEB J. 1996 Mar;10(4):517-24.</citation>
    <PMID>8647351</PMID>
  </reference>
  <reference>
    <citation>Berger SP, Hall S, Mickalian JD, Reid MS, Crawford CA, Delucchi K, Carr K, Hall S. Haloperidol antagonism of cue-elicited cocaine craving. Lancet. 1996 Feb 24;347(9000):504-8.</citation>
    <PMID>8596268</PMID>
  </reference>
  <verification_date>July 8, 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2006</study_first_submitted>
  <study_first_submitted_qc>April 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <keyword>Drug Cue</keyword>
  <keyword>Relapse</keyword>
  <keyword>Stress</keyword>
  <keyword>Craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

